Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: Identification of viral resistance mutations

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Sølund, Christina ^a,b   Krarup, Henrik ^c   Ramirez, Santseharay ^a,b   Thielsen, Peter ^a   Røge, Birgit T ^d   Lunding, Suzanne ^a   Barfod, Toke S ^e   Madsen, Lone G ^f   Tarp, Britta ^g   Christensen, Peer B ^h   Gerstoft, Jan ⁱ   Laursen, Alex L ^j   Bukh, Jens ^a,b   Weis, Nina ^a,b   Handest, Ulla Baslev ^a   Kristensen, Lena Hagelskjær ^a,k   Clausen, Mette Rye ^a,i   Møller, Axel ^a,d   Grønbæk, Karin ^a   Lindberg, Jens ^a,l   Nielsen, Henrik ^a,c   Schlichting, Poul ^a   Hansen, Jesper Bach ^a,c   Thomsen, Reimar ^a,j   more..

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d KOLDING HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

^f KØGE HOSPITAL   (Denmark)

^g SILKEBORG REGIONAL HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ Rigshospitalet   (Denmark)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k VIBORG HOSPITAL   (Denmark)

^l HERNING HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; ENZYME VARIANT; NONSTRUCTURAL PROTEIN 3; TELAPREVIR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DENMARK; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; RASH; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MUTATION; TREATMENT FAILURE; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DENMARK; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84914689390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113034     Document Type: Article

References (30)

1. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, et al. (2011) Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 66: 1673-1686. dkr215 [pii]; 10.1093/jac/dkr215 [doi].
2. Lange CM, Sarrazin C, Zeuzem S (2010) Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 32: 14-28. APT4317 [pii]; 10.1111/j.1365-2036.2010.04317.x [doi].
3. Pockros PJ (2011) Drugs in development for chronic hepatitis C: a promising future. Expert Opin Biol Ther 11: 1611-1622. 10.1517/14712598.2011.627851 [doi].
4. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, et al. (2011) Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52: 321-327. S1386-6532(11)00342-8 [pii]; 10.1016/j.jcv.2011.08.015 [doi].
5. Halfon P, Locarnini S (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206. S0168-8278(11)00079-1 [pii]; 10.1016/j.jhep.2011.01.011 [doi].
6. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J (2011) Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141: 1067-1079. S0016-5085(11)00761-X [pii]; 10.1053/j.gastro.2011.06.004 [doi].
7. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, et al. (2012) Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 9: 245. 1743-422X-9-245 [pii]; 10.1186/1743-422X-9-245 [doi].
8. Halfon P, Sarrazin C (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 32 Suppl 1: 79-87. 10.1111/j.1478-3231.2011.02716.x [doi].
9. Hansen N, Obel N, Christensen PB, Krarup H, Laursen AL, et al. (2009) Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat 16: 659-665. JVH1126 [pii]; 10.1111/j.1365-2893.2009.01126.x [doi].
10. Christensen PB, Clausen MR, Krarup H, Laursen AL, Schlichting P, et al. (2012) Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011. Dan Med J 59: C4465.
11. Corbet S, Bukh J, Heinsen A, Fomsgaard A (2003) Hepatitis C virus subtyping by a core-envelope 1- based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol 41: 1091-1100.
12. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, et al. (2007) Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 59 untranslated region sequences. J Clin Microbiol 45: 1102-1112. JCM.02366-06 [pii]; 10.1128/JCM.02366-06 [doi].
13. Krarup HB, Moller JM, Christensen PB, Fuglsang T, Ingerslev J, et al. (2000) Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 7: 435-439. jvh258 [pii].
14. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM (2007) Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46: 22-31. 10.1002/hep.21656 [doi].
15. Krarup HB, Drewes AM, Madsen PH (1998) A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 58: 415-422.
16. Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, et al. (2012) Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa- 2a and ribavirin in patients with chronic hepatitis C. Scand J Gastroenterol 47: 1115-1119. 10.3109/00365521.2012.694905 [doi].
17. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, et al. (2011) Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140: 667-675. S0016-5085(10)01596-9 [pii]; 10.1053/j.gastro.2010.10.056 [doi].
18. Wyles DL (2013) Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 207 Suppl 1:: S33-S39. jis761 [pii]; 10.1093/infdis/jis761 [doi].
19. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739. msr121 [pii]; 10.1093/molbev/msr121 [doi].
20. Vermehren J, Sarrazin C (2012) The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 26: 487-503. S1521-6918(12)00094-7 [pii]; 10.1016/j.bpg.2012.09.011 [doi].
21. Lauck M, Alvarado-Mora MV, Becker EA, Bhattacharya D, Striker R, et al. (2012) Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J Virol 86: 3952-3960.
22. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, et al. (2009) Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082.
23. Dusheiko G, Wedemeyer H (2012) New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 61: 1647-1652. gutjnl-2012-302910 [pii]; 10.1136/gutjnl-2012-302910 [doi].
24. Hansen N, Obel N, Christensen PB, Kjaer M, Laursen AL, et al. (2011) Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 11: 177. 1471-2334-11-177 [pii]; 10.1186/1471-2334-11-177 [doi].
25. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, et al. (2013) Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59: 434-441.
26. Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, et al. (2014) Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. Antiviral Res 105C: 112-117. S0166-3542(14)00062-X [pii]; 10.1016/j.antiviral.2014.02.019 [doi].
27. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, et al. (2013) Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 8: e55285. 10.1371/journal.pone.0055285 [doi]; PONE-D-12-34155 [pii].
28. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hezode C, et al. (2013) Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 10.
29. Li H, Hughes AL, Bano N, McArdle S, Livingston S, et al. (2011) Genetic diversity of near genomewide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One 6: e19562. 10.1371/journal.pone.0019562 [doi]; PONE-D-10-01855 [pii].
30. Domingo E, Sheldon J, Perales C (2012) Viral quasispecies evolution. Microbiol Mol Biol Rev 76: 159-216. 76/2/159 [pii]; 10.1128/MMBR.05023-11 [doi]